Advertisement

Cosmetic Uses of Botulinum Toxin

  • Jill A. Foster
  • Allan E. Wulc
  • Dan Straka
  • Kenneth V. Cahill
  • Craig Czyz
  • Jeremy Tan
Chapter

Abstract

Botulinum toxin (BoTX) has many applications as a tool in minimally invasive facial aesthetic treatments. These include diminishing kinetic facial wrinkle lines, softening prominent orbicularis ridges in the lower eyelids, elevating and contouring the eyebrow, relaxing the ridges of the contracted platysma, and bringing up the lateral corner of the mouth. Each of these is accomplished by using BoTX to relax specific combinations of facial musculature. Botulinum toxin is an effective treatment for glabellar frown lines, crow’s feet, vertical lip lines, and forehead lines by blocking innervation to the muscles contracting perpendicularly to the axis of the wrinkles. It is also possible to modify facial appearance by selectively weakening certain aspects of agonist and antagonist muscle groups. The treatment techniques discussed in this chapter are starting points and should be modified by the injecting surgeon based on experience and patient response.

Keywords

Botulinum toxin (BoTX) Clostridium botulinum Pharmacology BoTX-A BoTX-B Glabellar folds Horizontal forehead wrinkles Lateral periocular rhytides Brow repositioning Hypertrophic orbicularis Perioral wrinkles Melolabial folds Lateral oral commissures Platysmal bands 

Supplementary material

419986_5_En_16_MOESM1_ESM.mp4 (516.7 mb)
Video 16.1 Treatment mapping and injections (MP4 529115 kb)

References

  1. 1.
    Botox® label. Allergan, Inc, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5236lbl.pdf. Accessed 9 Oct 2016.
  2. 2.
    Dysport® label. Galderma, Lausanne, Switzerland. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125274s107lbl.pdf. Accessed 9 Oct 2016.
  3. 3.
    Xeomin® label. Merz, Frankfort Germany. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdf. Accessed 9 Oct 2016.
  4. 4.
    Myobloc® label. Solstice, San Diego, CA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103846s5120lbl.pdf. Accessed 9 Oct 2016.
  5. 5.
    Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, Wu Y, Vieira Braz A, Global Aesthetics Consensus Group, et al. Global aesthetics consensus: botulinum toxin type A--evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518e–29e.CrossRefPubMedGoogle Scholar
  6. 6.
    Schlessinger J, Gilbert E, Cohen JL, Kaufman J. New uses of AbobotulinumtoxinA in aesthetics. Aesthet Surg J. 2017;37(suppl_1):S45–58.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bonaparte JP, Ellis D, Quinn JG, Rabski J, Hutton B. A comparative assessment of three formulations of botulinum toxin type A for facial rhytides: a systematic review with meta-analyses. Plast Reconstr Surg. 2016;137(4):1125–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jill A. Foster
    • 1
    • 2
    • 3
    • 5
  • Allan E. Wulc
    • 6
    • 4
  • Dan Straka
    • 1
    • 2
    • 3
  • Kenneth V. Cahill
    • 1
    • 2
    • 3
  • Craig Czyz
    • 3
    • 5
  • Jeremy Tan
    • 1
    • 2
    • 3
  1. 1.Department of OphthalmologyThe Ohio State UniversityColumbusUSA
  2. 2.Department of OphthalmologyNationwide Children’s HospitalColumbusUSA
  3. 3.Plastic Surgery OhioEye Center of ColumbusColumbusUSA
  4. 4.Department of OphthalmologyDoctor’s Hospital, Ohio UniversityColumbusUSA
  5. 5.Wills Eye HospitalPhiladelphiaUSA
  6. 6.W Cosmetic SurgeryPlymouth MeetingUSA

Personalised recommendations